Michel Bolla.

Imaging was repeated in cases where medical or biochemical progression was suspected.15 Quality of life was assessed by using the EORTC core quality-of-life questionnaire ,16 supplemented by an early on version of the EORTC quality-of-lifestyle questionnaire for prostate cancers . Assessments had been made before preliminary treatment, at randomization, and 1, 1.5, 2.5, and 3.5 years following the start of irradiation. End Factors and Sample Size Overall survival, the primary end point, was thought as the time from randomization to death from any cause.In acromegaly, our treatment inhibits the production of the growth hormone receptor in the liver, which reduces levels of IGFI in the blood. This siRNA binds to an RNA-Induced Silencing Complex which separates both strands, acquiring one strand to a messenger RNA site to be cleaved to stop the production of the prospective protein. By comparison with our antisense drugs, RNAi is at a much less advanced stage of medical development. What do you consider the future holds for remedies acromegaly? At the moment, the drug treatments designed for individuals who fail first line therapy are very limited and require fairly frequent injections, mostly daily and occasionally normally as twice daily.